retatrutide phase 2 nejm 2023 obesity trial results SURPASS-2 (NEJM 2021) was the definitive head-to-head: tirzepatide vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type diabetes. All three tirzepatide doses produced superior HbA1c reductions Retatrutide Dosage: Titration Schedule |

Figure 1 3.1 Mitochondrial effects of exercise Aging is associated with a loss of mitochondrial capacity: muscle and other tissues tend to have fewer, smaller, and less efficient mitochondria as we grow older

How to handle semaglutide during travel

Yepoxidative stress

Patients should not purchase weight loss medicines from unregulated online pharmacies, as counterfeit products pose serious health risks

Animal Toxicology Studies Animal toxicology studies tested doses from 0.0027 mg/lb to 9.1 mg/lb via intraperitoneal, intramuscular, intravenous, and oral routes for up to 6 weeks, finding: No acute toxic or lethal dose No gross or histologic toxicity in major organs No hepatotoxicity or nephrotoxicity Negative Ames test (no mutagenicity) Negative chromosomal aberration tests (no genotoxicity) No teratogenicity in rat pregnancy studies No local injection site irritation The LD1 (minimum lethal dose) could not be achieved despite aggressive testing

The primary analysis was based on the dose assigned at randomization (planned treatment) and included data censored for COVID-19-related discontinuations, while a sensitivity analysis used the actual maintenance dose received (actual treatment) with on-treatment data only